Complementary Roles for Fibrin(ogen), Thrombospondin and vWF in Mediating Shear-dependent Aggregation of Platelets Stimulated at Threshold Thrombin Concentrations

Summary

We have evaluated the relative contribution of the adhesive ligands, von Willebrand factor (vWF), fibrinogen (Fg) and thrombospondin (TSP), all surface-expressed on washed platelets (WP) activated with a threshold thrombin concentration (~ 0.04 U/ml), to platelet micro-aggregation (PA) at shear rates (G) from 300-2000 s^-1. In suspensions of thrombin-activated WP sheared immediately (τ₀), all three ligands were required for optimal aggregation at all G, as shown by a 50-70% inhibition of capture efficiencies of PA (measured from initial rates of PA), by antibodies (Abs) directed against each protein. This aggregation involved both GPIb and GPIIbIIIa, as indicated by ~ 80% and 100% inhibition by Ab 6D1 and Ab 10E5, respectively. For WP preexposed to thrombin for 10 min to ensure maximal surface expression of secreted ligands and activated GPIIbIIIa (τ₁₀), vWF was predominantly required at all G (63-75% inhibition by anti-vWF Ab), together with TSP (35-50% inhibition by anti-TSP Ab). Under these conditions, Fg was extensively converted to fibrin, so that fibrin, rather than Fg, could participate in microaggregation, with GPIb less required than GPIIbIIIa as indicated by a 30-60% inhibition by Ab 6D1 as compared to 100% inhibition by Ab 10E5. Our results show that interactions between multiple ligands and receptors favour microaggregation depending on shear and thrombin activation conditions.

Keywords

vWF - fibin(ogen) - thrombospondin

• References

• 1 Xia A, Frojmovic MM. Aggregation efficiency of activated normal or fixed platelets in a simple shear field: Effect of shear and fibrinogen occupancy. Biophys J 1994; 66: 2190-201.
• 2 Savage B, Salvidar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-97.
• 3 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri Z. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40.
• 4 Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-66.
• 5 Tsuji S, Sugimoto M, Miyata S, Kuwahara M, Kinoshita S, Yoshioka A. Real-time analysis of mural thrombus formation in various platelet aggregation disorders: distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood 1999; 94: 968-75.
• 6 Frojmovic MM, Kasirer-Friede A, Goldsmith HL, Brown EA. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa. Thromb Haemost 1997; 77: 568-76.
• 7 Kasirer-Friede A, Frojmovic MM. Ristocetin and thrombin-induced platelet aggregation at physiological shear rates: Differential roles for GPIb and GPIIb-IIIa receptor. Thromb Haemost 1998; 80: 428-36.
• 8 Kasirer-Friede A, Legrand C, Frojmovic MM. Thrombin receptor occupancy modulates aggregation efficiency and platelet surface expression of von Willebrand factor and thrombospondin, at low thrombin concentrations. Thromb Haemost 1999; 81: 967-75.
• 9 Fressinaud E, Baruch D, Rothschild C, Baumgartner HR, Meyer D. Platelet von Willebrand factor: evidence for its involvement in platelet adhesion to collagen. Blood 1987; 70: 1214-7.
• 10 Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hrinda ME, McIntire LV. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Wille-brand factor binding to platelets. Blood 1993; 81: 1263-76.
• 11 Williams SB, McKeown LP, Krutzch H, Hansmann K, Gralnick HR. Purification and characterization of human platelet von Willebrand factor. Blood 1986; 68: 732-6.
• 12 Leung LLK. Role of thrombospondin in platelet aggregation. J Clin Invest 1984; 74: 1764-72.
• 13 Legrand C, Thibert V, Dubernard V, Begault B, Lawler J. Molecular requirements for the interaction of thrombospondin with thrombin-activated platelets: modulation of platelet aggregation. Blood 1992; 79: 1995-2003.
• 14 Tollefsen DM, Majerus PW. Inhibition of human platelet aggregation by monovalent antifibrinogen antibody fragments. J Clin Invest 1975; 1259-68.
• 15 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-8.
• 16 Roald HE, Sakariassen KS. Axial dependence of collagen-induced thrombus formation in flowing non-anticoagulated human blood. Anti-platelet drugs impair thrombus growth and increase platelet-collagen adhesion. Thromb Haemost 1995; 73: 126-31.
• 17 Barabino GA, Wise RJ, Woodbury VA, Zhang B, Bridges KA, Hebbel HP, Lawler J, Ewenstein BM. Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions. Blood 1997; 89: 2560-7.
• 18 Leung LLK, Nachman RL. Complex formation of platelet thrombospondin with fibrinogen. J Clin Invest 1982; 70: 542-9.
• 19 Legrand C, Dubernard V, Rabhile-Sabile S, Morandi da Silva V. Functional and clinical significance of thrombospondin. Platelets 1997; 8: 211-23.
• 20 Lozcalzo J, Inbal A, Handin RI. Von Willebrand protein facilitates platelet incorporation in polymerizing fibrin. J Clin Invest 1986; 78: 1112-9.
• 21 Rabhile-Sabile S, Thibert V, Legrand C. Thrombospondin peptides inhibit the secretion-dependent phase of platelet aggregation. Blood Coag Fibrinol 1996; 7: 237-40.
• 22 McEver RP, Martin MN. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J Biol Chem 1984; 259: 9799-804.
• 23 Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Wille-brand factor to platelets. J Biol Chem 1995; 270: 23352-61.
• 24 Matsueda GR. Bernatowicz Characterization of a monoclonal antibody that binds to the carboxyl-terminus of the fibrin gamma-chain. In: Mossesson MW. et al. (eds). Fibrinogen 3. Biochemistry, Biological functions, Gene Regulation and Expression, Proceedings of the International Fibrinogen Workshop. Elsevier; Milawaukee, WI: 1988: 133-6.
• 25 Lawler J, Derick LH, Connoly JE, Chen JH, Chao FC. The structure of human thrombospondin. J Biol Chem 1985; 260: 3762-72.
• 26 Legrand C, Dubernard V, Kieffer N, Nurden AT. Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. Eur J Biochem 1988; 171: 393-9.
• 27 Legrand C, Pidard D, Beiso P, Tenza D, Edelman L. Interaction of a monoclonal antibody to glycoprotein IV (CD36) with human platelets and its effects on platelet function. Platelets 1991; 2: 99-105.
• 28 Goldsmith HL, Frojmovic MM, Braovac S, McIntosh F, Wong T. Adenosine diphosphate-induced aggregation of human platelets in flow through tubes: III. Shear and extrinsic fibrinogen-dependent effects. Thromb Haemost 1994; 71: 78-90.
• 29 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Molec Immunol 1984; 21: 89-94.
• 30 Xia Z, Wong T, Liu Q, Kasirer-Friede A, Brown E, Frojmovic MM. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol 1996; 93: 204-14.
• 31 Frojmovic MM, Mooney RM, Wong T. Dynamics of platelet glycoprotein IIb-IIIa receptor expression and fibrinogen binding. I. Quantal activation of platelet subpopulations varies with adenosine diphosphate concentration. Biophys J 1994; 67: 2060-8.
• 32 Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-15.
• 33 Liu Q, Matsueda G, Brown E, Frojmovic MM. The AGDV residues on the gamma chain carboxyl terminus of the platelet-bound fibrinogen are needed for platelet aggregation. Biochim Biophys Acta 1997; 1343: 316-26.
• 34 Bonnefoy A, Legrand C, Frojmovic MM. Efficiency of platelet adhesion to fibrinogen depends on both cell activation and flow. Biophys J 2000; 78: 2834-43.
• 35 Frojmovic MM, Mooney RF, Wong T. Dynamics of platelet glycoprotein IIbIIIa receptor expression and fibrinogen binding. II. Quantal activation parallels platelet capture in stir-associated microaggregation. Biophys J 1994; 67: 2069-75.
• 36 Rooney MM, Farrell DH, van Hemel BM, de Groot PG, Lord ST. The contribution of the three hypothesized integrin-binding sites in fibrinogen to platelet-mediated clot retraction. Blood 1998; 92: 2374-81.
• 37 Schielen WJG, Adams HPHM, van Leuven K, Voskuilen M, Tesser GJ, Nieuwenhuizen W. The sequence gamma-(312-324) is a fibrin specific epitope. Blood 1991; 77: 2169-73.
• 38 Sixma JJ, van Hemel BM, Galanakis DK, Rooney MR, Scharrer I, de Groot PG. Mutations in the gamma chain of fibrinogen between γ315 and γ322 are associated with an absence of platelet adhesion under conditions of flow. Blood 1998; 92 (Supp I) 1432.
• 39 Endenburg SC, Hantgan RR, Lindeboom-Blokzijl L, Lankhof H, Jerome WG, Lewis JC, Sixma JJ, de Groot PG. On the role of von Willebrand factor in promoting platelet adhesion to fibrin in flowing blood. Blood 1995; 86: 4158-65.
• 40 Agbanyo FR, Sixma JJ, de Groot PG, Languino LR, Plow EF. Thrombospondin- platelet interactions: Role of divalent cations, wall shear rate, and platelet membrane glycoproteins. J Clin Invest 1993; 92: 288-96.
• 41 Ruggeri ZM, Dent JA, Salvidar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999; 94: 172-8.
• 42 Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest 2000; 105: 783-91.
• 43 Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-92.
• 44 Sudlow CLM, Baigent CN. Randomized trials of antiplatelet therapy. In: Rao GHR. (ed). Handbook of platelet physiology and pharmacology. Boston: Kluwer Academic Publishers; 1999. chapter 24: pps. 526-48.